GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » Additional Paid-In Capital

Genetic Technologies (STU:DU8) Additional Paid-In Capital : €0.00 Mil(As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Genetic Technologies Additional Paid-In Capital?


Genetic Technologies Additional Paid-In Capital Historical Data

The historical data trend for Genetic Technologies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Additional Paid-In Capital Chart

Genetic Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genetic Technologies Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genetic Technologies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Genetic Technologies Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (STU:DU8) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » Additional Paid-In Capital
Comparable Companies
ASX:RHY ASX:BDX ASX:LDX ASX:IBX ASX:CTE ASX:IIQ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT SHSE:603259 LH DGX XPAR:BIM
Traded in Other Exchanges
GENE:USA GTG:Australia
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Website
https://www.gtglabs.com
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (STU:DU8) Headlines

No Headlines